{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:14:32Z","timestamp":1793373272384,"version":"4.5.0"},"reference-count":12,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Synthetic opioids, such as the fentanyl analogue and nitazene drug class, are among the fastest growing types of opioids being detected in patients in the emergency department (ED) with illicit opioid overdose (OD). However, clinical outcomes from OD of novel potent opioids (NPOs), specifically nitazenes, are unknown aside from small case series.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine naloxone administration and clinical sequelae of patients who were in the ED with NPO overdose compared with fentanyl OD.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This is a cohort study subgroup analysis of adults admitted to the ED and tested positive for NPOs among in the ongoing nationwide ToxIC Fentalog cohort study from 2020 to 2022. Patients who were in the ED with a presumed acute opioid OD and residual blood samples were included, and those testing positive for NPOs were analyzed. Patients were included in this analysis if their confirmatory testing was positive for an NPO analyte, such as brorphine, isotonitazene, metonitazene, and\/or N-piperidinyl etonitazene. A comparison group included patients that were positive for fentanyl and devoid of any other analytes on toxicologic analysis.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Patients were exposed to NPOs, including brorphine, isotonitazene, metonitazene and\/or N-piperidinyl etonitazene.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was the total number of naloxone doses and total cumulative naloxone dose administered as part of routine clinical care following the OD. Naloxone requirements and clinical sequelae of NPO-positive patients were compared with those testing positive for fentanyl only.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n During the study period, 2298 patients were screened, of whom 717 met inclusion criteria, 537 had complete laboratory testing data, with 11 (2.0%) positive for only fentanyl and 9 (1.7%) positive for NPOs (brorphine, isotonitazene, metonitazene, or N-piperidinyl etonitazene). The age range of patients was aged 20 to 57 years (4 males [44.4%] and 5 females [55.6%]). The NPO group received a statistically significantly higher mean (SD) number of naloxone boluses in-hospital (1.33 [1.50]) compared with the fentanyl group (0.36 [0.92]) (\n P<\/jats:italic>\n \u2009=\u2009.02), which corresponded to a moderately large effect size (Cohen\n d<\/jats:italic>\n \u2009=\u20090.78). Metonitazene overdose was associated with cardiac arrest and more naloxone doses overall. Metonitazene cases had a mean (SD) number of 3.0 (0) naloxone doses, and 2 of 2 patients (100%) with metonitazene overdoses were administered cardiopulmonary resuscitation.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of patients admitted to the ED with confirmed opioid overdose testing positive for NPOs, in-hospital naloxone dosing was high compared with patients who tested positive for fentanyl alone. Further study is warranted to confirm these preliminary associations.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.31264","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T11:33:20Z","timestamp":1693308800000},"page":"e2331264","source":"Crossref","is-referenced-by-count":88,"title":["Naloxone Use in Novel Potent Opioid and Fentanyl Overdoses in Emergency Department Patients"],"prefix":"10.1001","volume":"6","author":[{"given":"Alexandra","family":"Amaducci","sequence":"first","affiliation":[{"name":"Lehigh Valley Health Network-USF Morsani College of Medicine, Allentown, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Aldy","sequence":"additional","affiliation":[{"name":"American College of Medical Toxicology, Phoenix, Arizona"},{"name":"Baylor University Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharan L.","family":"Campleman","sequence":"additional","affiliation":[{"name":"American College of Medical Toxicology, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao","family":"Li","sequence":"additional","affiliation":[{"name":"American College of Medical Toxicology, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Meyn","sequence":"additional","affiliation":[{"name":"American College of Medical Toxicology, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Abston","sequence":"additional","affiliation":[{"name":"American College of Medical Toxicology, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Culbreth","sequence":"additional","affiliation":[{"name":"American College of Medical Toxicology, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Krotulski","sequence":"additional","affiliation":[{"name":"Center for Forensic Science Research and Education at the Fredric Rieders Family Foundation, Willow Grove, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Logan","sequence":"additional","affiliation":[{"name":"Center for Forensic Science Research and Education at the Fredric Rieders Family Foundation, Willow Grove, Pennsylvania"},{"name":"NMS Labs, Horsham, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Wax","sequence":"additional","affiliation":[{"name":"American College of Medical Toxicology, Phoenix, Arizona"},{"name":"University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Brent","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex F.","family":"Manini","sequence":"additional","affiliation":[{"name":"NYC Health and Hospitals, Elmhurst, New York"},{"name":"Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Toxicology Investigators Consortium Fentalog Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie","family":"Buchanan","sequence":"additional","affiliation":[{"name":"for the Toxicology Investigators Consortium Fentalog Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Calello","sequence":"additional","affiliation":[{"name":"for the Toxicology Investigators Consortium Fentalog Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Carpenter","sequence":"additional","affiliation":[{"name":"for the Toxicology Investigators Consortium Fentalog Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Carey","sequence":"additional","affiliation":[{"name":"for the Toxicology Investigators Consortium Fentalog Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hendrickson","sequence":"additional","affiliation":[{"name":"for the Toxicology Investigators Consortium Fentalog Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Judge","sequence":"additional","affiliation":[{"name":"for the Toxicology Investigators Consortium Fentalog Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Levine","sequence":"additional","affiliation":[{"name":"for the Toxicology Investigators Consortium Fentalog Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Meaden","sequence":"additional","affiliation":[{"name":"for the Toxicology Investigators Consortium Fentalog Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Schwarz","sequence":"additional","affiliation":[{"name":"for the Toxicology Investigators Consortium Fentalog Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Shulman","sequence":"additional","affiliation":[{"name":"for the Toxicology Investigators Consortium Fentalog Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"issue":"7","key":"zoi230905r1","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1021\/acschemneuro.1c00064","article-title":"Synthesis, chemical characterization, and \u00b5-opioid receptor activity assessment of the emerging group of \u201cnitazene\u201d 2-benzylbenzimidazole synthetic opioids.","volume":"12","author":"Vandeputte","year":"2021","journal-title":"ACS Chem Neurosci"},{"issue":"9","key":"zoi230905r3","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1080\/15563650.2022.2084406","article-title":"Identification of a novel opioid, N-piperidinyl etonitazene (etonitazepipne), in patients with suspected opioid overdose.","volume":"60","author":"Calello","year":"2022","journal-title":"Clin Toxicol (Phila)"},{"issue":"9","key":"zoi230905r5","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/dta.v10.9","article-title":"Analysis of fentanyl analogs and novel synthetic opioids in blood, serum\/plasma, and urine in forensic casework.","volume":"10","author":"Moody","year":"2018","journal-title":"Drug Test Anal"},{"issue":"9","key":"zoi230905r6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/jat\/bkw086","article-title":"Analysis of novel synthetic opioids U-47700, U-50488 and furanyl fentanyl by LC-MS\/MS in postmortem casework.","volume":"40","author":"Mohr","year":"2016","journal-title":"J Anal Toxicol"},{"issue":"4","key":"zoi230905r7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/jat\/bkw012","article-title":"Analysis of MT-45, a novel synthetic opioid, in human whole blood by LC-MS-MS and its identification in a drug-related death.","volume":"40","author":"Papsun","year":"2016","journal-title":"J Anal Toxicol"},{"issue":"2","key":"zoi230905r8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/jat\/bkab082","article-title":"The rise and fall of isotonitazene and brorphine: two recent stars in the synthetic opioid firmament.","volume":"46","author":"Vandeputte","year":"2021","journal-title":"J Anal Toxicol"},{"issue":"6","key":"zoi230905r9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1080\/14740338.2019.1613372","article-title":"The role of take-home naloxone in the epidemic of opioid overdose involving illicitly manufactured fentanyl and its analogs.","volume":"18","author":"Kim","year":"2019","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"zoi230905r10","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/FTD.0000000000000970","article-title":"Acute intoxications and fatalities associated with benzimidazole opioid (nitazene analog) use: a systematic review.","volume":"44","author":"Montanari","year":"2022","journal-title":"Ther Drug Monit"},{"issue":"37","key":"zoi230905r11","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.15585\/mmwr.mm7137a5","article-title":"Notes from the field: nitazene-related deaths - Tennessee, 2019-2021.","volume":"71","author":"Roberts","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"zoi230905r2","unstructured":"Center for Forensic Science Research and Education. ToxIC Fentalog Study Group\u2014quarterly NPS report. Accessed March 27, 2023. https:\/\/www.cfsre.org\/nps-discovery\/clinical-reports"},{"key":"zoi230905r4","unstructured":"Revisions to the standards for the classification of federal data on race and ethnicity. Federal Register. Accessed July 27, 2023. https:\/\/www.govinfo.gov\/content\/pkg\/FR-1997-10-30\/pdf\/97-28653.pdf"},{"key":"zoi230905r12","unstructured":"Drug Overdose Death Rates. National Institute on Drug Abuse. Accessed March 3, 2023. https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2808868\/amaducci_2023_oi_230905_1692735433.08334.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T11:33:22Z","timestamp":1693308802000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2808868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.31264","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,29]]}}}